Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New lens aims to sharpen vision for LASIK patients with cataracts

NCT ID NCT07260695

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well a new type of cataract lens works for people who had LASIK surgery in the past. Cataracts cause blurry vision, and this lens is designed to help with seeing clearly at all distances. The study will involve 30 adults aged 50 and older who need cataract surgery in both eyes. Researchers will measure vision quality and how satisfied patients are after the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subjects MUST fulfill the following conditions to qualify for enrollment into the trial 1. Age: 50 years and older. 2. Gender: Males and Females. 3. Bilateral cataracts 4. Bilateral implantation of Odyssey IOLs (toric and non-toric) 5. Scheduled to undergo standard cataract surgery in both eyes, within 1 to 30 days between surgeries. 6. Willing and able to provide written informed consent for participation in the study. 7. Willing and able to comply with scheduled visits and study examination procedures. 8. Postoperative best corrected visual acuity of 0.2 logMAR (20/32 Snellen) or better in each eye. Exclusion Criteria: Subjects with ANY of the following conditions on the eligibility exam may NOT be enrolled into the trial. 1. Established ocular pathology, including: glaucoma (except glaucoma suspects), uveitis, and clinically-significant retinal pathology affecting the macula (with visual acuity worse than 20/25) and/or any other ocular findings that may, in the opinion of the investigator, affect vision. 2. Uncontrolled diabetes. 3. Use of any systemic or topical drug known to interfere with visual performance. 4. Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis. 5. Clinically significant corneal dystrophy. 6. Contact lens use during the active treatment portion of the trial. 7. Irregular astigmatism. 8. Corneal irregularities potentially affecting visual acuity (i.e., keratoconus, corneal opacities 9. History of chronic intraocular inflammation. 10. History of retinal detachment. 11. Pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules. 12. Previous intraocular surgery. 13. Previous keratoplasty 14. Previous refractive surgery other than myopic LASIK or PRK (i.e., radial keratotomy, hyperopic LASIK, etc) 15. Severe dry eye. 16. Pupil abnormalities. 17. Subject who may reasonably be expected to require a secondary surgical intervention at any time during the study (other than YAG capsulotomy, i.e., LASIK). 18. Any clinically significant, serious, or severe medical or psychiatric condition that may interfere with the interpretation of study results. 19. Participation in (or current participation) any ophthalmic investigational drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial. 20. Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.) 21. Abnormal iris The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates the patient is unsuitable for the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cataract are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Center For Sight

    RECRUITING

    Venice, Florida, 34285, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.